Clinical trial
A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian…
NCT00189358 · AGO Study Group, Other · Completed
Key facts
| NCT number | NCT00189358 |
|---|---|
| Title | A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy |
| Official title | A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy |
| Lead sponsor | AGO Study Group, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Cancer of the Fallopian Tube, Peritoneal Cancer |
| Intervention type | Drug |
| Interventions | ZD1839, tamoxifen |
| First posted | Sep 19, 2005 |
| Last update posted | Jul 20, 2010 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: